1. In Vivo
  2. >>Innovation

Medtronic and Genzyme Combine Their Cell Therapy Approaches to Serious Heart Disease

To help guide it through the world of cardiac biologics, Medtronic's enlisted the help of biotech Genzyme. Medtronic has drug delivery devices and imaging expertise: Genzyme offers focused cell therapy research in cardiac repair and heart disease and has an up-and-running Phase II trial using autologous skeletal myoblasts. Both companies label the deal as strategic--for now. But 2006 is presumably the earliest newly formed MG Biotherapeutics will begin to commit heavily to this problematic endeavor.

Medtronic Inc. is as well positioned as any device company to explore the first wave of opportunities for developing device/biologic combination products—and potentially revolutionize clinical therapy and the device industry. It has significant plays in two key areas, orthopedic biomaterials and drug eluding stents (DES), with Infuse (the bone-growth factor BMP-2, used in spine repair) and leading cardiac device businesses that should soon include a line of DES.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

From Brain Waves to Better Outcomes: Inside Alto Neuroscience’s Biomarker Strategy

 
• By David Wild

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.

Merck KGaA’s Digital Biomarker Strategy For Commercial Gains In Neurology

 
• By Jo Shorthouse

The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.

Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision Therapies

 
• By Jo Shorthouse

In Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.

Building The Worm Atlas For I&I Breakthroughs

 
• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

More from In Vivo

Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision Therapies

 
• By Jo Shorthouse

In Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Building The Worm Atlas For I&I Breakthroughs

 
• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.